Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
about
Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of MedulloblastomaRationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyrEvaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinomaA phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser.Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective studyManagement of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.The VEGF pathway in lung cancer.New therapeutic options for advanced forms of thyroid cancer.Immunohistochemical expression of potential therapeutic targets in canine thyroid carcinoma.Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography.A temporal examination of calcium signaling in cancer- from tumorigenesis, to immune evasion, and metastasis.
P2860
Q24615472-5E2D63D7-088B-48EE-9B68-A8CB979A9E68Q33990855-913339E4-8BCC-4DCD-AC18-91FFC56E2DE7Q34282488-E22FF384-CF0D-47CC-A174-5D3022097F76Q34330748-CC7EC464-590F-4504-B6C6-92D08B7D9D45Q35302906-4DF42636-27FD-4B0F-9BB6-4FACCCCADD54Q35811446-B2290025-311D-4800-9B6A-2875DC2E51C8Q35947278-A575062F-909B-4ED4-BD78-3739DDC34E26Q36118305-6F46BAAF-65A4-416C-986B-D5A2CC51FB9BQ36128415-F9BA09F5-1379-4469-A292-66227D4A99F6Q38148460-DBB00927-53EF-41F6-B866-F256C3C74C5FQ38192680-90399AF1-1763-4A0C-96AC-9EBFE6A2C9C5Q41055385-3041151C-76BC-4009-97F1-F8F5295EB44CQ42966149-DF70A98D-B4CA-4044-800D-D5198388FD47Q52720146-F585AD15-28FF-41A6-987F-6A2FAF60C2E6
P2860
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting vascular endothelial ...... nd extracellular implications.
@en
Targeting vascular endothelial ...... nd extracellular implications.
@nl
type
label
Targeting vascular endothelial ...... nd extracellular implications.
@en
Targeting vascular endothelial ...... nd extracellular implications.
@nl
prefLabel
Targeting vascular endothelial ...... nd extracellular implications.
@en
Targeting vascular endothelial ...... nd extracellular implications.
@nl
P2093
P1476
Targeting vascular endothelial ...... nd extracellular implications.
@en
P2093
Marc A Cohen
Marcia S Brose
Stephen M Keefe
P304
P356
10.1158/1078-0432.CCR-08-2743
P407
P577
2010-01-26T00:00:00Z